3D Medicines Partners with Sino Cellbiomed to Advance Tumor Immunotherapy Development
3D Medicines (HKG: 1244), a China-based oncology specialist, has entered into a partnership with Sino...
Cell-therapy
EMA’s CHMP Endorses Bristol Myers Squibb’s CAR-T Therapy Abecma for Multiple Myeloma
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
IASO Biotherapeutics Secures NMPA Approval for Fucaso in Refractory Myasthenia Gravis
China-based IASO Biotherapeutics has received clinical trial approval from the National Medical Products Administration (NMPA)...
GSK In-Licenses Elegen’s Cell-Free DNA Tech to Advance Next-Gen Gene Therapies and Vaccines
GlaxoSmithKline (GSK; NYSE: GSK), a UK-based pharmaceutical giant, has this week in-licensed US partner Elegen’s...
Tcelltech’s B7-H3 Targeting CAR-T Therapy TX103 Gets Tacit Clinical Approval for Glioblastoma
The Center for Drug Evaluation (CDE) website in China has indicated that Tcelltech’s TX103, a...
BriSTAR Immunotech’s LILRB4-Targeted Cell Therapy YTS104 Gets Tacit Approval for Clinical Trial in China
BriSTAR Immunotech, a clinical-stage cell therapy company based in Beijing, has received tacit clinical trial...
Legend Biotech’s Carvykti Files for European Approval as Second-Line MM Treatment
GenScipt Biotech Corp. (HKG: 1548), a China-based Contract Development and Manufacturing Organization (CDMO), through its...
Suzhou Jade Biomedical Partners with Hopstem Biotechnology for Cell Therapy Advancements
Suzhou Jade Biomedical Co., Ltd, a prominent player in the Chinese biotech industry, has entered...
Guangdong Aims to Boost Biomedicine Industry with Incentives and Strategic Development
The Guangdong Provincial Development and Reform Commission has unveiled an ambitious set of measures aimed...
Tasly Pharmaceuticals Gets NMPA Go-Ahead for Clinical Trial of Stem Cell Therapy in Heart Failure
Tasly Pharmaceuticals (SHA: 600535), a leading pharmaceutical company in China, has announced that it has...
CARsgen Therapeutics’ CT041 Shows Promising Results in Advanced Solid Tumors at ASCO GI 2024
China-based CAR-T cell specialist CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced the presentation of...
FDA Approves Casgevy, the First CRISPR-Based Gene Editing Therapy for β-Thalassemia
Casgevy (exagamglogene autotemcel), the pioneering gene editing therapy based on CRISPR technology, has received approval...
Shanghai-Based NK CellTech Earns FDA IND Clearance for Non-Genetically Modified NK Cell Therapy
NK CellTech, a Shanghai-based developer of NK cell therapies, has announced that it has received...
Boai NKY Medical Holdings Partners with HuaDao Biopharma for CAR-T Therapy Incubator
Boai NKY Medical Holdings Ltd (SHE: 300109), a Chinese biotech company, has announced a strategic...
Fosun Kite and Medi Cover Launch First Value-Based Payment Plan for Lymphoma Treatment
Fosun Kite and Medi Cover, a health management and patient service platform under Sinopharm (HKG:...
Lion TCR Partners with MaxCyte to Develop mRNA-Based TCR-T Therapies for Solid Tumors and Viral Diseases
Lion TCR, a Singapore-based clinical-stage biotechnology company with backing from Chinese investors, has entered into...
JW Therapeutics Secures NMPA Review for CAR-T Therapy in Mantle Cell Lymphoma
JW Therapeutics (HKG: 2126), a Chinese biopharmaceutical company, has announced that it has submitted an...
ImmunoTech Biopharm Commences Patient Enrollment in Phase II Study for CAR-T-19 Injection
ImmunoTech Biopharm Ltd, a China-based specialist in chimeric antigen receptor T-cell (CAR-T) therapies (HKG: 6978),...
GenScipt Subsidiary Legend Biotech Finalizes Licensing Deal with Novartis for DLL3 CAR-T Therapies
GenScipt Biotech Corp., a China-based Contract Development and Manufacturing Organization (CDMO) (HKG: 1548), has announced...
JW Therapeutics and 2seventy Bio Ink Exclusive Deal for CAR-T Cell Therapy in Greater China
JW Therapeutics (HKG: 2126), a biopharmaceutical company based in China, has announced an exclusive collaboration...